Amendment No. 1 to Exclusive License Agreement between The Washington University and Chromadex, Inc.
Contract Categories:
Intellectual Property
›
License Agreements
Summary
This amendment updates the Exclusive License Agreement between The Washington University and Chromadex, Inc., originally signed in 2013. It replaces the milestones, payments, and diligence requirements related to the licensed technology, specifying new sales targets, payment amounts, and timelines for various product fields, including dietary supplements, consumer foods, research reagents, and pharmaceuticals. All other terms of the original agreement remain unchanged. The amendment is effective as of December 15, 2015, and is signed by authorized representatives of both parties.
EX-10.5 9 ex10-5.htm MATERIAL CONTRACTS SEC Connect
Exhibit 10.5
AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENT
This Amendment #1 (“First Amendment”) is made and entered into on December 15, 2015 (“First Amendment Effective Date”) by and between The Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as “WU”) and Chromadex, Inc., a corporation of the State of California, having a place of business at 10005 Muirlands Blvd., Suite G, Irvine, CA 92618 (hereinafter referred to as “Licensee”), each a “Party” or collectively the “Parties” of this Agreement.
WHEREAS, WU and Licensee entered into an Exclusive License Agreement (WU Contract No. 004446-011) on March 4, 2013 (“ELA”);
WHEREAS, certain information in the ELA was designated “TBD” in the “Milestone and Payments” table on page 1 and in the Exhibit F “Diligence Milestones” table;
NOW THEREFORE, in consideration of the foregoing and the agreements below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
1.
The Milestones and Payments table in the Preamble on page 1 is replaced in its entirety with the following:
Market | Milestone | Approximate Timing | Payment |
Field 1 (dietary supplement, sports nutrition, functional foods, skin care/cosmetic) | Commercial-scale production | 12 months | $2K |
Cumulative sales >3kg | 18 months | $5K | |
$200K cumulative sales | 24 months | $10K | |
$1M cumulative sales | 36 months | $15K | |
Field 2 (food/beverage with FDA approval) | Cumulative sales >3kg | 36 months | $5K |
Cumulative sales >20kg | 48 months | $10K | |
Field 3 (consumer foods) | Cumulative sales >3kg | 24 months | $5K |
$100K cumulative sales | 36 months | $10K | |
$500K cumulative sales | 48 months | $15K | |
Field 4 (research reagents) | $5K cumulative sales | 24 months | $500 |
$10K cumulative sales | 36 months | $1k | |
Field 5 (pharmaceutical) | IND application filed for neurological disease | EOY 2018 | $20K |
Phase 1 initiation | EOY 2019 | $20K | |
Phase 2 initiation | EOY 2020 | $25K | |
Phase 3 initiation | EOY 2021 | $50K | |
NDA approval | EOY 2024 | $100K | |
First commercial sale | EOY 2024 | $250K |
2.
The Diligence Milestones table in Exhibit F is replaced in its entirety with the following:
Market | Milestone | Timing |
Field 1 (dietary supplement, sports nutrition, functional foods, skin care/cosmetic) | Commercial-scale production | 12 months |
Cumulative sales >3kg | 18 months | |
$200K cumulative sales | 24 months | |
$1M cumulative sales | 36 months | |
Field 2 (food/beverage with FDA approval) | Cumulative sales >3kg | 36 months |
Cumulative sales >20kg | 48 months | |
Field 3 (consumer foods) | Cumulative sales >3kg | 24 months |
$100K cumulative sales | 36 months | |
$500K cumulative sales | 48 months | |
Field 4 (research reagents) | $5K cumulative sales | 24 months |
$10K cumulative sales | 36 months | |
Field 5 (pharmaceutical) | IND application filed for neurological disease | EOY 2018 |
Phase 1 initiation | EOY 2019 | |
Phase 2 initiation | EOY 2020 | |
Phase 3 initiation | EOY 2021 | |
NDA approval | EOY 2024 | |
First commercial sale | EOY 2024 |
The Parties hereby agree to amend the terms of the ELA as provided above, effective as of the First Amendment Effective Date. Where the ELA is not explicitly amended, the terms of the ELA will remain in force. Definitions used in this First Amendment that are not otherwise defined herein shall have the meanings such terms are given in the ELA.
IN WITNESS WHEREOF, the authorized representatives of the parties hereto have executed this Amendment by affixing their signatures below on the date(s) indicated:
Chromadex, Inc. | Washington University |
| |
By: /s/ Troy Rhonemus Name: Troy Rhonemus Title: COO Date: 1/2/2016 | By: /s/ Nichole Mercier Name: Nichole Mercier, Ph.D. Title: Interim Director, OTM Date: 12.21.15 |